Role of oral teriflunomide in the management of multiple sclerosis

Radu Tanasescu,1,2 Nikos Evangelou,1 Cris S Constantinescu1 1Academic Division of Clinical Neurology, University of Nottingham, Nottingham, UK; 2Department of Neurology, Colentina Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Abstract: The landscape of the treatment...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tanasescu R, Evangelou N, Constantinescu CS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/80d40c8d91304dd493f0e94de2b27fd1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:80d40c8d91304dd493f0e94de2b27fd1
record_format	dspace
spelling	oai:doaj.org-article:80d40c8d91304dd493f0e94de2b27fd12021-12-02T02:55:18ZRole of oral teriflunomide in the management of multiple sclerosis1176-63281178-2021https://doaj.org/article/80d40c8d91304dd493f0e94de2b27fd12013-04-01T00:00:00Zhttp://www.dovepress.com/role-of-oral-teriflunomide-in-the-management-of-multiple-sclerosis-a12834https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Radu Tanasescu,1,2 Nikos Evangelou,1 Cris S Constantinescu1 1Academic Division of Clinical Neurology, University of Nottingham, Nottingham, UK; 2Department of Neurology, Colentina Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Abstract: The landscape of the treatment of relapsing–remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing–remitting multiple sclerosis, while others have completed Phase III trials and are awaiting review for registration. Teriflunomide is a pyrimidine synthesis inhibitor with selective immunomodulatory and immunosuppressive properties that have shown consistent efficacy in clinical trials, and a good safety profile. This paper provides an overview of the mechanisms of action and efficacy and safety results from clinical trials with this drug. The role of teriflunomide in the treatment of relapsing–remitting multiple sclerosis is discussed. Keywords: teriflunomide, multiple sclerosis, oral drugs, clinical trialsTanasescu REvangelou NConstantinescu CSDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 539-553 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Tanasescu R Evangelou N Constantinescu CS Role of oral teriflunomide in the management of multiple sclerosis
description	Radu Tanasescu,1,2 Nikos Evangelou,1 Cris S Constantinescu1 1Academic Division of Clinical Neurology, University of Nottingham, Nottingham, UK; 2Department of Neurology, Colentina Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Abstract: The landscape of the treatment of relapsing–remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing–remitting multiple sclerosis, while others have completed Phase III trials and are awaiting review for registration. Teriflunomide is a pyrimidine synthesis inhibitor with selective immunomodulatory and immunosuppressive properties that have shown consistent efficacy in clinical trials, and a good safety profile. This paper provides an overview of the mechanisms of action and efficacy and safety results from clinical trials with this drug. The role of teriflunomide in the treatment of relapsing–remitting multiple sclerosis is discussed. Keywords: teriflunomide, multiple sclerosis, oral drugs, clinical trials
format	article
author	Tanasescu R Evangelou N Constantinescu CS
author_facet	Tanasescu R Evangelou N Constantinescu CS
author_sort	Tanasescu R
title	Role of oral teriflunomide in the management of multiple sclerosis
title_short	Role of oral teriflunomide in the management of multiple sclerosis
title_full	Role of oral teriflunomide in the management of multiple sclerosis
title_fullStr	Role of oral teriflunomide in the management of multiple sclerosis
title_full_unstemmed	Role of oral teriflunomide in the management of multiple sclerosis
title_sort	role of oral teriflunomide in the management of multiple sclerosis
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/80d40c8d91304dd493f0e94de2b27fd1
work_keys_str_mv	AT tanasescur roleoforalteriflunomideinthemanagementofmultiplesclerosis AT evangeloun roleoforalteriflunomideinthemanagementofmultiplesclerosis AT constantinescucs roleoforalteriflunomideinthemanagementofmultiplesclerosis
_version_	1718402052046979072

Role of oral teriflunomide in the management of multiple sclerosis

Ejemplares similares